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Abstract
Background: Treatment of individuals with asymptomatic carotid artery stenosis is still handled controversially.
Recommendations for treatment of asymptomatic carotid stenosis with carotid endarterectomy (CEA) are based on
trials having recruited patients more than 15 years ago. Registry data indicate that advances in best medical treatment
(BMT) may lead to a markedly decreasing risk of stroke in asymptomatic carotid stenosis. The aim of the SPACE-2 trial
(ISRCTN78592017) was to compare the stroke preventive effects of BMT alone with that of BMT in combination with
CEA or carotid artery stenting (CAS), respectively, in patients with asymptomatic carotid artery stenosis of 70%
European Carotid Surgery Trial (ECST) criteria.
Methods: SPACE-2 is a randomized, controlled, multicenter, open study. A major secondary endpoint was the cumulative
rate of any stroke (ischemic or hemorrhagic) or death from any causewithin 30 days plus an ipsilateral ischemic strokewithin
one year of follow-up. Safety was assessed as the rate of any stroke and death from any cause within 30 days after CEA
or CAS. Protocol changes had to be implemented. The results on the one-year period after treatment are reported.
Findings: It was planned to enroll 3550 patients. Due to low recruitment, the enrollment of patients was stopped
prematurely after randomization of 513 patients in 36 centers to CEA (n¼ 203), CAS (n¼ 197), or BMT (n¼ 113). The
one-year rate of the major secondary endpoint did not significantly differ between groups (CEA 2.5%, CAS 3.0%, BMT
0.9%; p¼ 0.530) as well as rates of any stroke (CEA 3.9%, CAS 4.1%, BMT 0.9%; p¼ 0.256) and all-cause mortality (CEA
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2.5%, CAS 1.0%, BMT 3.5%; p¼ 0.304). About half of all strokes occurred in the peri-interventional period. Higher albeit
statistically non-significant rates of restenosis occurred in the stenting group (CEA 2.0% vs. CAS 5.6%; p¼ 0.068) without
evidence of increased stroke rates.
Interpretation: The low sample size of this prematurely stopped trial of 513 patients implies that its power is not
sufficient to show that CEA or CAS is superior to a modern medical therapy (BMT) in the primary prevention of
ischemic stroke in patients with an asymptomatic carotid stenosis up to one year after treatment. Also, no evidence for
differences in safety between CAS and CEA during the first year after treatment could be derived. Follow-up will be
performed up to five years. Data may be used for pooled analysis with ongoing trials.
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Introduction
The prevalence of asymptomatic carotid artery stenosis
(ACS) >50% is about 1%–2% in the general popula-
tion1,2 (US/European or Korean population) and
increases with age 70 years up to 12.5% in men and
6.9% in women.3 Choice of treatment for patients with
ACS still varies considerably among and within coun-
tries4 and is a matter of debate.5,6 Two interventional
methods such as carotid endarterectomy (CEA) and
carotid artery stenting (CAS) compete with best med-
ical treatment (BMT) alone. Guidelines recommending
interventional treatment of ACS refer to data of two
large randomized trials (Asymptomatic Carotid
Atherosclerosis Study (ACAS) and Asymptomatic
Carotid Surgery Trial 1 (ACST-1)) having compared
CEA with conservatively treated control groups more
than 15 years ago. ACAS7 showed in 1995 an annual
risk of ipsilateral stroke in medically treated patients of
2.2% and ACST-18 in 2004 a risk of about 1%.
Since then a decline in stroke risk has been shown9,10
and an increasing number of retrospective analyses indi-
cates quite low annual stroke rates of about 1% or less
under modern intensive BMT.11–15 On the other hand,
publications with low stroke rates of ACS under BMT
have been criticized for mixing patients with low-grade
(50%–69%) and high-grade (70%) stenosis, having
small patient numbers, not reporting adherence to
BMT, neglecting transient ischemic attack (TIA)/high-
risk plaque morphology and consecutive carotid
revascularization (therefore preventing stroke), or discri-
minating insuﬃciently between ipsilateral and contralat-
eral events.16 Furthermore, two independent studies
showed much higher annual rates of ipsilateral ischemic
events in BMT (2.9% in a group of 1121 patients17 and
2.4% in a group of 794 patients18). However, inACST-1,
lipid-lowering therapy showed lower rates of long-term
stroke in both groups,19 indicating that stroke risk
decreases with intensive medical therapy including
statin medication9 by plaque stabilization and consecu-
tive reduction of microembolization.20–23
To establish any beneﬁt of interventional therapies
over BMT alone, peri-interventional complications
such as stroke, myocardial infarction, and death
have to be taken into account. The peri-interventional
risk of stroke within the ﬁrst 30 days in the asymptom-
atic cohort of the Carotid Revascularization
Endarterectomy Versus Stenting Trial (CREST) was
reported with 1.4% for CEA and 2.5% for CAS.24,25
In the Asymptomatic Carotid Trial (ACT-I), it was
1.4% for CEA and 2.8% for CAS.26 Data collected
outside randomized controlled trials indicate even
higher stroke rates27,28 Regarding composite endpoints
including stroke, death, and myocardial infarction, the
peri-interventional risk for patients with ACS partially
exceeded 3%: Within the ﬁrst 30 days from interven-
tion, it amounted to 3.6% for CEA and 3.5% in CAS in
CREST24,25 and to 2.6% for CEA and to 3.3% for
CAS in ACT-I.26 Considering the low risk rate under
modern pharmacotherapy, interventional therapies
have to prove at least non-inferiority to BMT alone.29
In order to attain a higher evidence level for treat-
ment of ACS based upon optimal current treatment
options, randomized controlled trials comparing CEA
with CAS with a third medical arm were requested.30–33
Up to now, no data of randomized controlled trials
with a BMT arm have been published. The SPACE-2
trial was initiated in 2009 comparing both interven-
tional methods to BMT alone. Due to low recruitment
rates, further enrollment had to be stopped prema-
turely.34 Data from the one-year follow-up examination
are presented in this publication.
Methods
In a randomized, controlled, multicenter, open trial, we
recruited patients with asymptomatic stenosis of the
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common and/or internal carotid artery of at least 70%
European Carotid Surgery Trial (ECST) criteria equiva-
lent to at least 50% North American Symptomatic
Carotid Endarterectomy Trial (NASCET) criteria
(ISRCTN78592017). Stenoses were considered asymp-
tomatic ifhaving causedno ipsilateralneurological deﬁcits
(amaurosis fugax (AF), TIA, or stroke)within the last 180
days.Weenrolled patients in36 study centers inGermany,
Switzerland, andAustria. Risks of stroke, death, myocar-
dial infarction, and restenosis were analyzed for three
treatment modalities: BMT alone vs. CEAþBMT vs.
CASþBMT. BMT was deﬁned as up-to-date medication
following national and international guidelines (see
Supplementary Table S11). Details about trial rationale,
design, sample size, selection of study patients, and quali-
ﬁcation of interventionalists have been published previ-
ously.34,35 SPACE-2 started in 2009. Due to insuﬃcient
recruitment rates, a change in study design was imple-
mented in 2013.36 However, the continuing low recruit-
ment rates led to the premature termination of enrollment
of the SPACE-2 study in 2014. Vascular risk factors were
controlled regularly at screening visit, intervention, and
one day (one month and six months) after intervention
and every year after randomization.
This paper reports results on eﬃcacy and safety for
the one-year period after treatment. The primary eﬃ-
cacy endpoint of SPACE-2 (cumulative rate of any
stroke or death from any cause within 30 days plus
an ipsilateral ischemic stroke within ﬁve years of
follow-up) will be reported later.
Endpoints
The composite major secondary endpoint is deﬁned as
cumulative rates of any stroke or death from any cause
within 30 days plus ipsilateral ischemic stroke within
one year of follow-up. Secondary and tertiary end-
points were single components of the one-year end-
point, cardiac events, restenosis (recurrent stenosis of
at least 70%ECST following ultrasound criteria37), tech-
nical failures, and observations at diﬀerent time points.
In the interventional groups, safety was assessed as the
rate of any stroke within 30 days from intervention and
death from any cause within 30 days. TIA was deﬁned
as temporary neurologic deﬁcits lasting less than 24 h.
A relevant disabling stroke was deﬁned having a mod-
iﬁed Rankin score scale of more than two 30 days after
stroke. Vascular death was deﬁned as any death due to
stroke, myocardial infarction, or hemorrhage as well as
any death that were not clearly non-vascular.
Statistical analysis
Details on the sample size calculation are given in the
Supplement. The primary analysis is intention to treat
(ITT). Also, a per-protocol analysis (PPA) is performed
after excluding patients who did not ﬁnish therapy or
showed other serious protocol violations. Time-to-
event analyses were performed by Kaplan–Meier esti-
mators, and Cox proportional hazards regression.
Event rates within a ﬁxed time period (for example,
during ﬁrst 30 days or during the ﬁrst year) were ana-
lyzed with chi-square test, Fisher’s exact test, or logistic
regression. Several subgroup analyses were predeﬁned
(age, sex, and number of vascular risk factors including
hypertension, diabetes, coronary heart disease, hyper-
lipidemia, and smoking). Technical aspects (e.g. use of
a protection system, stent design, use of shunts, ever-
sion technique vs. endarterectomy) were analyzed for
the respective groups. Analyses were performed with
STATA/IC 13.0 (College Station, TX, USA).
The study was approved by the ethics committee of
the University of Heidelberg, Germany (S-311/2008).
Results
Study recruitment
A total of 513 patients were recruited in 36 centers. Of
these, 203 patients were randomized into the CEA
group (39.6%), 197 into the CAS group (38.4%), and
113 into the BMT group (22.0%). For details concern-
ing applied treatment, protocol violation and loss to
follow-up see Figure 1.
Baseline characteristics
Baseline characteristics did not diﬀer substantially
between the three study arms except for occlusion of
the contralateral carotid artery, mainly in CAS group
(Table 1). Medication at baseline did not diﬀer between
groups except for the use of diuretics. Over 80% of
patients were treated with statins prior to intervention.
In CAS, embolic protection devices (EPDs) were used
in 36.0%; in addition, 62.7% of CEA were performed
in general anesthesia. For details of medication and
intervention procedures, see Supplementary Table S1,
peri- and postprocedural complications other than
stroke, death, or myocardial infarction in the interven-
tional groups are described in Supplementary Table S2.
Endpoint events within 30 days
For the interventional approaches, the safety endpoint
30-day complication rate (any stroke or death) did not
exceed 3%: 2.5% in CEA and 2.5% in CAS. At the day
of intervention, four strokes occurred after CEA (2.0%,
all ipsilateral) and three strokes after CAS (1.5%, all
ipsilateral). Further strokes occurred in the CEA group
on day 2 (contralateral) and in the CAS group on days
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11 and 22 (both ipsilateral) after intervention. No
stroke occurred in the BMT group within the ﬁrst 30
days; no patient died or had a myocardial infarction.
Stroke risk did not diﬀer signiﬁcantly between CEA,
CAS and BMT (p¼ 0.240; Table 2). In the CEA and
CAS groups, there were no pre-interventional endpoint
events after randomization and before intervention.
One-year major secondary endpoint
Altogether 12 patients (2.3%) suﬀered a one-year major
secondary endpoint event. The endpoint occurred ﬁve
times in the CEA group (2.5%), six times in the CAS
group (3.0%), and once in the BMT group (0.9%;
Table 3). Compared to BMT, the hazard ratio for the
one-year major secondary endpoint was 2.82 in CEA
(p¼ 0.345, 95% conﬁdence interval (CI) 0.33–24.07)
and 3.50 in CAS (p¼ 0.246; 95% CI 0.42–29.11).
Details are shown in Figure 2 and described in Table 3.
Centers did not diﬀer evidently regarding incidence
of major secondary endpoint. The volume of patients
treated per center did not show evident inﬂuence on
major secondary endpoint either.
Risk factors for the one-year major secondary
endpoint
The following analyses are exploratory. General anes-
thesia, use of a shunt, or clamping duration in CEA
were not related with higher risk of major secondary
outcome events. In CEA and CAS, the side of interven-
tion was associated with major secondary endpoint
events (4.8% of left-treated CEA; 0% of right-treated
CEA, p¼ 0.060; 6.5% of right-treated CAS; and 0% of
left-treated CAS, p¼ 0.009). In all CAS patients with
major secondary outcome events, no embolic protec-
tion system was used. For further details of risk factors
for major secondary endpoint, see Supplementary
Table S3. The type of stent used for CAS did not
relate with major secondary outcome event
(Supplementary Table S4).
Secondary one-year results
Within one year, 17 patients (3.3%) had either an ipsi-
lateral or contralateral stroke. This endpoint occurred
eight times in the CEA group (3.9%, four ipsilateral
Figure 1. Randomization and follow-up of the study patients within one year. All patients included in intention-to-treat analysis.
PAOD: Peripheral arterial occlusive disease; CHD: coronary heart disease; ASA: acetylsalicylic acid; CAS: carotid artery stenting;
BMT: best medical treatment; CEA: carotid endarterectomy.
203 allocated to CEA
• 190 received allocated treatment
• 13 treated with other therapy:
1 CAS (patient decision)
12 BMT (3x clopidogrel and 
ASA due to CHD)
513 patients randomised
197 allocated to CAS
• 178 received allocated treatment
• 19 treated with other therapy:
6 CEA (3x CAS technical fail: 2x
puncture of artery not possible, 1x 
fail of dilatation due to calcified 
stenosis)
12 BMT (1x CAS technical fail: 
Stent could not be placed over 
stenosis, 1 x grade of stenosis in 
angiography <70%)
1 treatment not known
113 allocated to BMT
• 111 received allocated treatment
• 2 treated with other therapy:
1 CEA (patient decision)
1 treatment not known (patient 
decision)
BMT
8 lost to follow-up
CEA
17 lost to follow-up
CAS
21 lost to follow-up
3 violation of in-/exclusion criteria: 
1 patient with allergy to ASA 
(clopidogrel used)
1 patient with allergy to heparine 
(ASA used)
1 patient with age at inclusion 49
Analyzed: 203 treated with CEA
2 violation of in-/exclusion criteria:
1 pmRS 2 (due to PAOD1)
1 patient with age at inclusion 48
Analyzed: 197 treated with CEA
1 violation of in-/exclusion criteria:
1 pmRS 3 (mobility with walking 
stick due to total hip replacement 
surgery)
Analyzed: 113 treated with CEA
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and four contralateral), eight times in the CAS group
(4.1%, six ipsilateral and two contralateral) and once in
the BMT group (0.9%, ipsilateral). Compared to BMT,
the hazard ratio for any stroke was 4.51 in CEA
(p¼ 0.155, 95% CI 0.56–36.09) and 4.70 in CAS
(p¼ 0.144, 95% CI 0.59–37.61). The risk of ipsilateral
stroke was higher in the early phase (81.8% of all ipsi-
lateral strokes occurred in ﬁrst 30 days). The risk of
Table 1. Baseline characteristics of the study population, according to treatment group.
CEA (n¼ 203) CAS (n¼ 197) BMT (n¼ 113) Total (n¼ 513)
Male sex (% of patients) 151 (74.4%) 143 (72.6%) 87 (77.0%) 381 (74.3%)
Age (years, median (IQR)) 70 (64, 75) 70 (63, 75) 68 (64, 74) 70 (64, 75)
Side randomized: left 105 (51.7%) 105 (53.3%) 49 (43.4%) 259 (50.5%)
Ipsilateral symptomsa 16 (7.9%) 8 (4.1%) 5 (4.4%) 29 (5.7%)
Grade of stenosisb (median (IQR)) 80 (75, 85) 80 (75, 85) 80 (75, 85) 80 (75, 85)
Grade of contralateral stenosisb 20 (0, 50) 30 (0, 60) 10 (0, 55) 20 (0, 55)
Contralateral occlusion 3 (1.5%) 12 (6.1%) 3 (2.7%) 18 (3.5%)
Systolic BPc (median (IQR)) 147 (131, 160) 145 (130, 162) 150 (133, 160) 146 (130, 160)
Diastolic BPc (median (IQR)) 80 (72, 88) 80 (74, 90) 80 (75, 89) 80 (73, 89)
Hypertension (% of patients) 180 (88.7%) 177 (89.8%) 102 (90.3%) 459 (89.5%)
Diabetes 52 (25.6%) 59 (29.9%) 40 (35.4%) 151 (29.4%)
Coronary heart disease 70 (34.5%) 72 (36.5%) 40 (35.4%) 182 (35.5%)
Hypercholesterolemia 158 (77.8%) 158 (80.2%) 91 (80.5%) 407 (79.3%)
Current smoker 45 (22.2%) 31 (15.7%) 24 (21.2%) 100 (19.5%)
Past smoker 91 (44.8%) 99 (50.3%) 67 (59.3%) 257 (50.1%)
Cholesterold (median (IQR)) 181 (153, 209) 173.5 (152, 200) 169.5 (146.5, 192.5) 174 (151, 203)
Glucosed (median (IQR)) 103.5 (92, 121) 104 (93, 125) 104 (92, 119) 104 (92.5, 122)
HbA1c in % (median (IQR)) 6 (5.7, 6.45) 6 (5.7, 6.6) 5.9 (5.55, 6.75) 6 (5.7, 6.5)
Number of vascular risk factors 2 (2, 3) 3 (2, 3) 3 (2, 3) 3 (2, 3)
HDLd (median (IQR)) 48 (40, 62) 49 (40, 56.5) 49 (41.5, 57.5) 49 (41, 58)
LDLd (median (IQR)) 105 (81, 130) 98.5 (80, 126) 97 (80, 117) 99 (80, 123.5)
Triglycerided (median (IQR)) 131 (98, 182.5) 128.5 (92, 184) 120 (91, 181) 126.5 (94, 182)
BMI (median (IQR)) 27 (25, 30) 27 (25, 30) 27 (24, 29) 27 (25, 30)
Time delaye (median (IQR)) 14 (8, 21) 14 (8, 21) – 14 (8, 21)
Note: Continuous variables are given as medians with interquartile range (lower and upper quartiles), and as n (%) for categorical variables. Dashes
indicate not applicable; IQR: interquartile range; CAS: carotid artery stenting; BMT: best medical treatment; CEA: carotid endarterectomy; BP: blood
pressure; BMI: body mass index; HDL: High-densitiy lipoprotein; LDL: Low-density lipoprotein.
a>180 days on side of randomized carotid artery.
b% ECST.
cBP in mm Hg.
dmg/dl.
eTime from randomization to treatment (days).
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isolated ipsilateral stroke beyond 30 days from inter-
vention dropped down to 0% in CEA and 0.5% in
CAS. For more details, also on further endpoints, see
Figure 2 and Table 3. Within the ﬁrst year, four
patients (0.8%) had a (relevant) disabling stroke: two
times in the CEA group (1.0%), once in the CAS group
(0.5%), and once in the BMT group (0.9%). Two dis-
abling strokes occurred within 30 days after
Table 3. Endpoint event rates (95% confidence interval) within the first year; n¼ 513.
CEA (n¼ 203) CAS (n¼ 197) BMT (n¼ 113) p
One-year major secondary endpoint (n¼ 12) 5 (2.5%; 0.8%–5.7%) 6 (3.0%; 1.1%–6.5%) 1 (0.9%; 0.0%–4.8%) 0.530
Any stroke (n¼ 17) 8 (3.9%; 1.7%–7.6%) 8 (4.1%; 1.8%–7.8%) 1 (0.9%; 0.0%–4.8%) 0.256
Any stroke after d30a (n¼ 7) 3 (1.5%; 0.3%–4.3%) 3 (1.5%; 0.3%–4.4%) 1 (0.9%; 0.0%–4.8%) 1.000
Ipsilateral stroke (n¼ 11) 4 (2.0%; 0.5%–5.0%) 6 (3.0%; 1.1%–6.5%) 1 (0.9%; 0.0%–4.8%) 0.497
Ipsilateral stroke after d30a (n¼ 2) 0 (0.0%; 0.0%–1.8%) 1 (0.5%; 0.0%–2.8%) 1 (0.9%; 0.0%–4.8%) 0.521
Disabling strokeb (n¼ 4) 2 (1.0%; 0.1%–3.5%) 1 (0.5%; 0.0%–2.8%) 1 (0.9%; 0.0%–4.8%) 1.000
Any death (n¼ 11) 5 (2.5%; 0.8%–5.7%) 2 (1.0%; 0.1%–3.6%) 4 (3.5%; 1.0%–8.8%) 0.304
Myocardial infarction (n¼ 1) 1 (0.5%; 0.0%–2.7%) 0 (0.0%; 0.0%–1.9%) 0 (0.0%; 0.0%–3.2%) 1.000
Restenosisc (n¼ 15) 4 (2.0%; 0.5%–5.0%) 11 (5.6%; 2.8%–9.8%) – 0.068
Rec- or progressived stenosis (n¼ 20) 4 (2.0%; 0.5%–5.0%) 11 (5.6%; 2.8%–9.8%) 5 (4.4%; 1.5%–10.0%) 0.158
TIA (n¼ 15) 4 (2.0%; 0.5%–5.0%) 5 (2.5%; 0.8%–5.8%) 6 (5.3%; 2.0%–11.2%) 0.230
Ipsilateral TIA (n¼ 12) 2 (1.0%; 0.1%–3.5%) 4 (2.0%; 0.6%–5.1%) 6 (5.3%; 2.0%–11.2%) 0.063
Note: Dashes indicate not applicable. CAS: carotid artery stenting; BMT: best medical treatment; CEA: carotid endarterectomy; : Fisher’s exact test;
TIA: transient ischemic attack; if 0%: Confidence interval one-sided 97.5%.
aAfter intervention for CEA/CAS and after randomization for BMT.
bmRS 30 days after stroke> 2.
cOnly in CEA and CAS.
dOnly in BMT.
Table 2. Periprocedural period (d0–d30): Incidence of stroke, death, and myocardial infarction (95% confidence interval; n¼ 513;
intention to treat).
CEA (n¼ 203) CAS (n¼ 197) BMT (n¼ 113) p
Any stroke or death until d30a 5 (2.5%; 0.8%–5.7%) 5 (2.5%; 0.8%–5.8%) Not applicable 0.962b
Any stroke at d0 (only CEA/CAS)c 4 (2.0%; 0.5%–5.0%) 3 (1.5%; 0.3%–4.4%) Not applicable 1.000
Any stroke until d30d 5 (2.5%; 0.8%–5.7%) 5 (2.5%; 0.8%–5.8%) 0 (0.0%; 0.0%–3.2%) 0.240
Ipsilateral stroke until d30d 4 (2.0%; 0.5%–5.0%) 5 (2.5%; 0.8%–5.8%) 0 (0.0%; 0.0%–3.2%) 0.238
Myocardial infarctione 0 (0.0%; 0.0%–1.8%) 0 (0.0%; 0.0%–1.9%) 0 (0.0%; 0.0%–3.2%)
Any deathe 0 (0.0%; 0.0%–1.8%) 0 (0.0%; 0.0%–1.9%) 0 (0.0%; 0.0%–3.2%)
Note: CAS: carotid artery stenting; BMT: best medical treatment; CEA: carotid endarterectomy; : Fisher’s exact test; if 0%: Confidence interval one-
sided 97.5%.
aSafety endpoint, evaluated after intervention only in patients randomized to CEA or CAS.
bv2 test.
cDay of intervention.
dAfter intervention for CEA/CAS and after randomization for BMT.
eAfter randomization.
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Figure 2. Kaplan–Meier estimates of cumulative incidence (%) for major outcomes within one year. (a) Major secondary end-
point. (b) Any stroke. (c) Any stroke after day 30 up to one year.** (d) Ipsilateral stroke.** (e) Any death. (f) Restenosis 70%ECST
in CEA and CAS. (g) Ipsilateral TIA.** (h) Disabling stroke.** CAS: carotid artery stenting; BMT: best medical treatment; CEA:
carotid endarterectomy; CI: confidence interval; HR: hazard ratio.
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intervention (one in CEA and one in CAS). Compared
to CAS, the hazard ratio for disabling stroke was 1.92
in CEA (p¼ 0.593, 95% CI 0.17–21.22) and 1.71 in
BMT (p¼ 0.703, 95% CI 0.11–27.40) Figure 2 and
Table 3 present corresponding details. Non-disabling
strokes (n¼ 13) and disabling strokes did not diﬀer
between study groups (p¼ 0.246; Supplementary
Table S5).
Within one year, 11 patients (2.1%) died (of vascular
or other reasons). This endpoint occurred ﬁve times in
the CEA group (2.5%), two times in the CAS group
(1.0%), and four times in the BMT group (3.5%).
Compared to CAS, the hazard ratio for any death
was 2.37 in CEA (p¼ 0.303, 95% CI 0.46–12.21) and
3.35 in BMT (p¼ 0.163, 95% CI 0.61–18.28). For
details, see Figure 2 and Table 3. Regarding reasons
of death, one cardiac death occurred in the CEA and
CAS group, respectively (0.5%). No cardiac death
occurred in the BMT group (for details, see
Supplementary Table S6).
Within one year, 15 (3.8%) patients treated within the
CEA or CAS group, respectively, had a restenosis of
70%ECST. This endpoint occurred 4 times in the
CEA group (2.0%) and 11 times in the CAS group
(5.6%). None of the patients with restenosis had a
major secondary endpoint event, a stroke (ipsilateral or
contralateral), or TIA. Compared to CEA, the hazard
ratio for restenosis was 2.89 in CAS (p¼ 0.069, 95% CI
0.92–9.08). For details, see Figure 2 and Table 3. The
median time to detection of restenosis did not diﬀer
between CEA and CAS (CEA 201.5 days (p25: 194,
p75: 282.5) vs. CAS 198 days (p25: 177, p75: 364);
p¼ 0.896). Five patients in the BMT group (4.4%)
showed a progressive stenosis (increasing grade of sten-
osis, above 70%ECST) that lead to neurological symp-
toms <24h and in four cases to intervention. None of
these patients suﬀered a major secondary outcome event
or any stroke. For details, see Supplement Figure S1.
Within one year, 15 patients (2.9%) suﬀered a
neurologically proven TIA localized ipsilateral or
contralateral to the randomized stenosis. TIA occurred
four times in the CEA group (2.0%), ﬁve times in the
CAS group (2.5%), and six times in the BMT group
(5.3%). Within these TIA patients, three had an AF (2
CEA, 1 BMT). No patient within the CEA/CAS group
with a restenosis suﬀered a TIA. Among TIA patients,
cerebral imaging showed infarction in three patients
with CAS (not all patients with TIA received cerebral
imaging). Compared to CEA, the hazard ratio for any
TIA was 1.30 in CAS (p¼ 0.693, 95% CI 0.35–4.86)
and 2.66 in BMT (p¼ 0.129, 95% CI 0.75–9.43;
Supplement Figure S2). In four of the ﬁve patients
with TIA and cerebral imaging, clinical silent infarction
was detected. Seven patients of the BMT group
received CEA or CAS after TIA and/or progressive
stenosis. Ipsilateral TIA occurred two times in the
CEA group (1.0%), four times in the CAS group
(2.0%), and 6 times in the BMT group (5.3%).
Compared to CEA, the hazard ratio for ipsilateral
TIA was 5.34 in BMT (p¼ 0.040, 95% CI 1.08–26.44)
and 2.09 in CAS (p¼ 0.396, 95% CI 0.38–11.39,
Figure 2 and Table 3). Most TIAs (any or only ipsilat-
eral) in CEA/CAS patients occurred peri-intervention-
ally, whereas TIA in the BMT group occurred in the
follow-up period. Two of the six patients with ipsilat-
eral TIA in the BMT group (33.3%) had a progressive
stenosis to 75% or 100%, respectively (odds ratio
17.33; p¼ 0.006).
Per-protocol analysis
The PPA did not reveal relevant diﬀerences to the ITT
analysis. Regarding outcome events, none of the
patients excluded in the PPA or with diﬀerent therapy
from randomization had a major secondary outcome
event, any stroke, TIA, restenosis, or myocardial
infarction. One patient randomized to CEA and treated
with BMT died. For details, see Supplement Figures S4
to S6 and Supplementary Tables S8 to S10.
Discussion
It was planned to enroll 3550 patients into the rando-
mized, controlled, multicenter, open SPACE-2 trial. Due
to low recruitment, the enrollment of patients was
stopped prematurely after randomization of 513 patients
in 36 centers to CEA (n¼ 203), CAS (n¼ 197) or BMT
(n¼ 113). Here, we report the one-year results of these
513 patients. One year after enrollment patients in the
interventional groups had more major secondary end-
point events than the BMT group (CEA 2.5%, CAS
3.0% vs. BMT 0.9%). Within these 513 patients, no
stroke was prevented with interventional therapies com-
pared to BMT alone within one year.
Relating to safety concerns, the 30-day stroke/death
rate remained under the guideline recommendation of
3% for interventional therapies,38 and we found no dif-
ference between CEA and CAS. Also within one year,
no diﬀerences for stroke or death were found between
CEA and CAS. In a pooled meta-analysis of 3019
patients (including data of CREST and ACT-1),39
CAS trended toward an increased risk of periprocedural
stroke/death compared to CEA. In comparison to pre-
viously published data of CREST (CEA 1.4%, CAS
2.5%)25 and ACT-1 (CEA 1.7%, CAS 2.9%),26 the
CEA group in SPACE-2 showed slightly higher 30-day
stroke/death rates; for CAS, our 30-day stroke/death
rates accorded with the previously published data of
CREST and ACT-1. In both interventional groups,
stroke risk primarily increased due to peri-interventional
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ipsilateral strokes and decreased considerably after-
wards. Thirty days after CEA or CAS, a stroke risk
lower than in only BMT-treated patients should be
expected. However, within the ﬁrst year after interven-
tion, the overall risk of stroke in CEA and CAS
exceeded the stroke risk in the BMT group.
Although 64% of patients in the SPACE-2 CAS
group were treated without EPDs, the risk of any
stroke within the ﬁrst 30 days was comparable to
data of patients treated with distal EPD.25,26 Also,
other data indicate that an EPD might be waived
with asymptomatic plaques.40
With only one (however disabling) stroke in the
BMT group and a risk rate of 0.9%, it could not be
proven that patients have a beneﬁt from intervention
within the ﬁrst year after the procedure. Thus, for inter-
ventional treatment, a selection of patients with ele-
vated stroke risk is important and also strongly
recommended by recent guidelines.41–43
The annual stroke risk of our BMT treated patients
was below the 2.2% shown in ACAS7 but still higher
than reported risks below 0.5% in a well-controlled
cohort in Oxford.12 The low stroke risk in our
BMT group may be related to inclusion of patients
with lower grade of stenosis (70%ECST) with a
median of 80%ECST. However, the rate of ipsilateral
TIA—partially with proof of cerebral infarction—was
with 5.3% in BMT more than twice as high as in the
interventional groups and showed a signiﬁcant diﬀer-
ence. Concerning relevant disabling strokes (mRS> 2),
stroke rates were quite low and not signiﬁcantly diﬀer-
ent between all groups. Regarding death, no diﬀerences
between groups were found, and reasons of death
were predominantly non-vascular. The death rate in
SPACE-2 did not exceed death rates for patients with
ACS.44 Concerning our data, carotid revascularization
does not seem to be indicated for prevention of vascular
death. Less patients than presumed suﬀered a myocar-
dial infarction. This may be related to the strict deﬁn-
ition (see deﬁnition of myocardial infarction in
Supplementary Material).
CAS was not signiﬁcantly associated with higher
rates of restenosis than CEA and restenosis did not
lead to any TIA, stroke, or major secondary outcome
events in both interventional groups. In contrast, pro-
gressive stenosis in BMT group was signiﬁcantly corre-
lated with a high risk for ipsilateral TIA. However,
none of the BMT-patients with a progressive stenosis
suﬀered a major secondary outcome or any stroke
events. In a retrospective study of 214 patients with a
median follow-up of 13 years, progression of stenosis
was not correlated with ipsilateral ischemic events45
either, but the majority of published data contradicts
this ﬁndings and report an increased risk in progressing
stenosis.17,46–48 The ﬁve-year results of the SPACE-2
collective may get clearer results on this issue.
Considerably lower restenosis rates especially in CAS
were found in ACT-I (at one year 0.6% in CAS and
2.6% in CEA).26
The age modifying eﬀect preferring CEA in patients
older than 70 years has been described in symptomatic
carotid stenosis.25,49,50 With its limited sample size,
SPACE-2 failed to validly demonstrate this eﬀect
(Supplement Figure S3).
In patients with ACS, ﬁrst and foremost the focus
should be placed on intensive conservative treatment
not only including statin medication but also strict
management of hypertension, diabetes, smoking cessa-
tion, and lifestyle modiﬁcation as health diet and phys-
ical activity. These factors have shown to reduce risk of
ischemic events or progression of stenosis.14,41 In spe-
ciﬁc cases, selected patients with high-risk stenosis (e.g.
cerebral microembolization, intraplaque hemorrhage,
echolucent plaque formation, silent embolic infarcts
on brain imaging, or reduced cerebral blood ﬂow
reserve) should be considered for treatment with inter-
ventional methods.41,51–53 Assessing the beneﬁt after
CEA or CAS, patient age and life expectancy have to
be taken into account.54
The most relevant limitation of our study is the low
sample size as a consequence of the premature recruit-
ment stop because of insuﬃcient patient enrollment.
Thus, the analyses presented have to be interpreted
with caution. A further limitation was due to the fact
that routine cerebral magnetic resonance imaging was
not part of the study protocol and thereby silent infarc-
tion could not be detected in all cases. Within one year,
four patients with clinically silent cerebral infarction
could be identiﬁed. However, one important aim has
been achieved: Providing data for pooled analysis with
ongoing trials comparing CEA/CAS with a BMT arm in
ACS as CREST-2,55 ECST-2,56 or ACTRIS.57
Conclusions
Due to a reduced sample size and low power, interpret-
ation of SPACE-2 results is diﬃcult. The follow-up
data of one year did not show a better preventive
eﬀect for stroke by CEA or CAS over BMT alone in
patients with ACS. However, patients with BMT alone
had more TIA. Regarding interventional therapies,
CAS did not diﬀer from CEA in terms of safety and
eﬃcacy. Higher rates of restenosis with CAS did not
diﬀer signiﬁcantly and were not associated with ele-
vated stroke rates. A further follow-up of SPACE-2
patients will be performed for the ﬁve years period
after treatment. Data are for pooled analysis and may
support the planning of new trials and allow individual
data meta-analyses when combined with the data of
ongoing trials.
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